ResearcherChengdu Medical CollegeActive in the last 2 years

Yan Feng

Provisional: name at one institution (moderate confidence, 0.60), identity_conf@1As of 8 November 2026

Known by name at one institution; no external author ID yet. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 1

Papers, trials and grants by year

2022: 1 paper · 2023: none · 2024: none · 2025: none · 2026: 1 paper

Papers 2

Efficacy and safety of EGFR monoclonal antibody combined with gemcitabine-based chemotherapy in first-line treatment of locally advanced unresectable or metast… Co-author DOI 10.1080/14737140.2025.2576624 ↗
Establishment of a prognostic prediction system based on tumor microenvironment of pancreatic cancer. Co-author DOI 10.1097/md.0000000000032364 ↗

Closest collaborators

The 1 strongest of 1 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Ke Xu · 2 shared papers, 2022–2026 · strength 0.72
- Paper Efficacy and safety of EGFR monoclonal antibody combined with gemcitabine-based chemotherapy in first-line treatment of… DOI 10.1080/14737140.2025.2576624 ↗
- Paper Establishment of a prognostic prediction system based on tumor microenvironment of pancreatic cancer. DOI 10.1097/md.0000000000032364 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.